TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04746924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo infusions will consist of a sterile, normal saline solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions will consist of a sterile, normal saline solution.
Study: NCT05716672

Intervention type: DRUG
Intervention: Lazertinib
Description: Lazertinib 240mg(3tablets, 80mg/1tablet), once a day(QD), oral(PO), until disease progression or unacceptable toxicity

Intervention type: DRUG
Intervention: Lazertinib
Description: Lazertinib 240mg(3tablets, 80mg/1tablet), once a day(QD), oral(PO), until disease progression or unacceptable toxicity
Study: NCT05243849

Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography
Description: Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).

Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography
Description: Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).
Study: NCT06394167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Solution for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Solution for IV administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for IV administration.
Study: NCT05479903

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computerized cognitive training system
Description: One-on-one cognitive training by an experienced cognitive therapist, combined with an existing computerized cognitive training system

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aerobic exercise
Description: Patients are trained by experienced physical therapists with the help of elastic bands and physical therapy devices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tranditional cognitive training
Description: One-on-one cognitive training with an experienced cognitive therapist, combined with traditional cognitive training methods (e.g., balls, cards, counting, daily conversation, etc.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
Study: NCT06394167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for IV administration.
Study: NCT05479903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment
Description: Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment
Description: Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
Study: NCT05848661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AUDISSEE
Description: AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AUDISSEE
Description: AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AUDISSEE
Description: AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AUDISSEE
Description: AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.
Study: NCT05312008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo
Description: Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo
Description: Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
Study: NCT05537545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue grafting
Description: A pouch is made in the buccal mucosa using microsurgical instruments. Thereupon, a free gingival graft is harvested from the palatal mucosa in the premolar area and de-epithelialized to arrive at a CTG of about 1 mm thickness. Height and length are tailored to the dimensions of the site. Then, the CTG is brought into the pouch and fixed with two single sutures (Seralon 6/0, Serag Wiessner, Naila, Germany) onto the buccal mucosa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue grafting
Description: A pouch is made in the buccal mucosa using microsurgical instruments. Thereupon, a free gingival graft is harvested from the palatal mucosa in the premolar area and de-epithelialized to arrive at a CTG of about 1 mm thickness. Height and length are tailored to the dimensions of the site. Then, the CTG is brought into the pouch and fixed with two single sutures (Seralon 6/0, Serag Wiessner, Naila, Germany) onto the buccal mucosa.
Study: NCT06124235

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Coated Orthodontic Miniscrews with Chlorhexidine Hexametaphosphate Nanoparticles
Description: insertion:~1. According to the random number generated, the corresponding envelop for left and right side by chosen.~2. The patient will be asked to brush his/her teeth.~3. The patient will rinse his/her mouth with chlorhexidine mouth rinse (0.12%) just before surgery being at least half an hour after brushing.~The miniscrews used conical shaped, self-drilling, 1.6 mm in diameter, 8mm in length made of Ti.~1. The site of insertion determined from the x-ray by using stent that will be fabricated for accurate site for OMS.~2. Infiltration LA will be administered. Approximately 0.45 mL ,injected into the alveolar mucosa above the OMS placement site, in order to provides an acceptable anesthesia, while still allowing the patient feedback in case the OMS contacting the periodontal ligament (PDL).~3. OMS will be placed manually by screw driver on buccally at an angle 90 degrees and then adjusted to the appropriate angle.~4. x-ray will be taken to confirm OMS position.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated Miniscrew with Chlorhexidine Hexametaphosphate Nanoparticles
Description: Non-coated orthodontic miniscrews
Study: NCT06573970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD), and executive dysfunction. Dispensing of blinded medication (40mg to 80mg ATX or placebo) will begin at randomization and will be dispensed at weeks 2, 4, 8, and 12. The initial dose of ATX is 40mg or placebo and will be given for one week, the dose will be titrated to 80mg if tolerated in the second week through week 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
Study: NCT06229912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given by PO
Study: NCT05515185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT095 CAR-T injection
Description: Clearance of lymphocytes
Study: NCT05125601

Intervention type: OTHER
Intervention: The Parents' Evaluation of Aural/Oral Performance of Children (PEACH)
Description: The Parents' Evaluation of Aural/Oral Performance of Children (PEACH) will be completed once.
Study: NCT05649228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.1% Cream
Description: A small amount of cream about the size of a U.S. quarter containing 0.10% non-palmitated capsaicin will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin 0.1% Cream
Description: A small amount of cream about the size of a U.S. quarter containing 0.10% non-palmitated capsaicin will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Palmitate 0.25% Cream
Description: A small amount of cream about the size of a U.S. quarter containing 0.25% capsaicin palmitate will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin Palmitate 0.25% Cream
Description: A small amount of cream about the size of a U.S. quarter containing 0.25% capsaicin palmitate will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cream
Description: A small amount of cream about the size of a U.S. quarter will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Cream
Description: A small amount of cream about the size of a U.S. quarter will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
Study: NCT05279482

Intervention type: OTHER
Intervention: observation for outcome of methylprednisolone dose
Description: no intervention as it is retrospective study for outcome

Intervention type: OTHER
Intervention: observation for outcome of methylprednisolone dose
Description: no intervention as it is retrospective study for outcome
Study: NCT04086030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training
Description: Patients will undergo standardized postoperative rehabilitation program including blood flow restriction training. Exercises will be performed with BFR at 80% LOP.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Blood Flow Restriction Training
Description: Patients will undergo standardized postoperative rehabilitation program where exercises will be performed with sham BFR pressure of 20 mmHG.
Study: NCT05541432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised strength training (group 1)
Description: Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of 10-12 repetitions at an intensity of \~70% of estimated 1 repetition maximum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised strength training (group 2)
Description: Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of \~4-6 repetitions at an intensity of 85% of estimated one repetition maximum, with a warm-up set of 8 repetitions at their estimated 70% estimated one repetition maximum to attempt to match the volume performed in the other resistance training group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Participants in this arm will complete twice-weekly upper and lower body exercises at home, focused on posture and balance. Participants will meet 1:1 with an exercise physiologist who will select and prescribe exercises. Participants will also be invited to attend twice monthly virtual exercise and education sessions.
Study: NCT04625413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: UR-GOAL communication tool
Description: The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awarene
Study: NCT05106465

Intervention type: DEVICE
Intervention: Konectom platform
Description: Administered as specified in the treatment arm.
Study: NCT06677190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: A Hypoxia-Inducible Factor-2 alpha inhibitor, 40 mg immediate-release tablet, taken orally per protocol.
Study: NCT05083221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hear-Talk-Activity audiological program
Description: The participants were randomly assigned to either the experimental group or the waiting-list control group, using a computer-generated list of random numbers.
Study: NCT03806439

Intervention type: OTHER
Intervention: Radical cystectomy.
Description: Adult patients undergoing radical cystectomy.
Study: NCT05763238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTERVENTION GROUP
Description: Preoperative Protocol:~DAY 1: Incentive spirometry 1 set of 2 repetitions(each repetition includes 05 deep inhalations) 3 times a day.~Active ROMS (3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 10 steps thrice a day. DAY 2: Incentive spirometry 1 set of 3 repetitions (each repetition includes 08-10 deep inhalation) 3 times a day.~Active ROMS, 3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 15 steps thrice a day. DAY 3: Incentive spirometry,1 set of 3 repetitions(each repetition includes 10 deep inhalation) 3 times a day Active ROMS 3 sets of 5 repetitions of both upper and lower limbs thrice a day. Walk, Static marching to 20 steps thrice a day. Postoperative Protocol: Conventional protocol of respective cardiac setup

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP
Description: Preoperative: Patients' parents will be educated about the disease process, surgery, it's possible complications, and precautions.~Postoperative: Conventional protocol of respective cardiac setup
Study: NCT03226626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD
Description: Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD
Description: Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SubQKath
Description: The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
Study: NCT06257914

Intervention type: DIAGNOSTIC_TEST
Intervention: Catquest-9SF
Description: Measurement of self-assessed visual function with Catquest-9SF, measurement of ocular aberrations with iTrace (Tracey Technologies), and straylight measurements with C-Quant (Oculus)
Study: NCT05007353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Lifestyle Intervention
Description: Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Guided Intervention
Description: In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
Study: NCT05062057

Intervention type: DEVICE
Intervention: Adhesive ambulatory ECG recording patches
Description: All women in both groups will undergo sequential placement of two 14-day adhesive ambulatory ECG recording patches for a total of 28 days of ECG recording

Intervention type: DEVICE
Intervention: Adhesive ambulatory ECG recording patches
Description: All women in both groups will undergo sequential placement of two 14-day adhesive ambulatory ECG recording patches for a total of 28 days of ECG recording
Study: NCT06031233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Gradual shortening of infusion times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Gradual shortening of infusion times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Gradual shortening of infusion times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Gradual shortening of infusion times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Gradual shortening of infusion times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Gradual shortening of infusion times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Gradual shortening of infusion times
Study: NCT06226363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNF1901 Monoclonal Antibody Injection
Description: LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
Study: NCT05825690

Intervention type: OTHER
Intervention: Retrospective evaluation of specific brain MRI features
Description: Initial brain MRI and subsequent follow-up studies will be reviewed to document the presence of specific MRI features, and their association with greater disease severity in the acute phase and/or neurological sequelae after encephalitis resolution will be investigated. More specifically, we will analyze the presence of:~* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry
Study: NCT04577963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Oral VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Oral VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: PD-1 inhibitor
Study: NCT05162092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Participants will be given Conventional Physiotherapy. It included Passive Soft tissue elongation of tight muscles, Lower limb resistance exercises, Movement transitions, balance board and foam board standing, walking and stair climbing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation with conventional physiotherapy
Description: Participants in group B will be given conventional physiotherapy and vestibular stimulation exercises. It included conventional is same as given to the conventional and Vestibular Stimulation
Study: NCT05497726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node detection using intravenous bevacizumab-800CW
Description: Sentinel lymph node detection using intravenous bevacizumab-800CW
Study: NCT05281263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPI-RSV-F Vaccine (BLB-201)
Description: see arm/group description

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPI-RSV-F Vaccine (BLB-201)
Description: see arm/group description
Study: NCT04530162

Intervention type: PROCEDURE
Intervention: Ultrasound guided nerve block
Description: nerve block using bupivacaine and dexamethasone.